Filing Details
- Accession Number:
- 0001209191-19-057610
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-11-21 16:21:10
- Reporting Period:
- 2019-11-19
- Accepted Time:
- 2019-11-21 16:21:10
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1242825 | M Jeffrey Leiden | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Ceo & President | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-11-19 | 64,032 | $109.14 | 170,378 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2019-11-19 | 32,502 | $131.89 | 202,880 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-11-19 | 62,886 | $210.41 | 139,994 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-11-19 | 23,033 | $211.43 | 116,961 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-11-19 | 10,615 | $212.75 | 106,346 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2019-11-19 | 64,032 | $0.00 | 64,032 | $109.14 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2019-11-19 | 32,502 | $0.00 | 32,502 | $131.89 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2025-02-02 | No | 4 | M | Direct | |
| 0 | 2025-07-20 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 440 | Indirect | 401(k) |
Footnotes
- Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $210.41 (range $210.06 to $210.83).
- Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $211.43 (range $211.08 to $211.97).
- Open market sales reported on this line occurred at a weighted average price of $212.75 (range $212.30 to $212.97).
- Fully vested.
Billionaire Hedge Funds
